New combo aims to calm immune attack in transplant patients
NCT ID NCT01453140
First seen Apr 14, 2026 · Last updated Apr 30, 2026 · Updated 2 times
Summary
This study tested a mix of drugs (cyclophosphamide, sirolimus, and azacitidine) to help patients whose graft-versus-host disease (GVHD) did not improve with steroids. GVHD is a serious condition where donor immune cells attack the patient's body after a stem cell transplant. The goal was to boost regulatory T cells to control the immune response. Only 3 patients were enrolled before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VERSUS HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Conditions
Explore the condition pages connected to this study.